San Diego, CA, USA – July 8, 2011 — HUYA Bioscience International, a leader in globalizing China’s biopharmaceutical innovations, today announced a strategic partnership with the Liaoning (Benxi) Bio-Pharmaceutical Industry Base. The collaboration agreement will combine both parties’ strength in aiding the advancement of China’s drug innovation platform.
HUYA is one of the first companies to have recognized China’s potential to help meet the global need for new preclinical and clinical stage compounds. The company is committed to facilitating and promoting the global development and commercialization of novel pharmaceutical products originating in China. HUYA has established a series of collaborations with leading universities and research institutions throughout China and has pioneered in-licensing clinical stage compounds from the country, utilizing its expertise to advance these compounds for global markets.
Liaoning (Benxi) Bio-pharmaceutical Industry Base is the third national biomedical industry base approved by the National Ministry of Science and Technology. Located between Benxi and Shenyang, Liaoning (Benxi) Bio-pharmaceutical Industry Base is now the northeast pharmaceutical center and has attracted both domestic and foreign pharmaceutical companies and research institutions to assemble at this base, including Shenyang Pharmaceutical University, Liaoning Analytical Science Research Institute, and Liaoning TCM Research Institute.
Under the agreement, Liaoning (Benxi) Bio-pharmaceutical Industry Base and HUYA will collaborate to promote new drug development. HUYA will have the first opportunity to provide assistance in evaluating research and development projects conducted by pharmaceutical enterprises residing in Liaoning (Benxi) Bio-pharmaceutical Industry Base. HUYA will also be able to globalize select programs from Liaoning (Benxi) Bio-pharmaceutical Industry Base through HUYA’s innovative co-development model and worldwide pharmaceutical partners.
“It’s a great honor to form partnership with Liaoning (Benxi) Bio-pharmaceutical Industry Base,” said Clement Gingras, HUYA’s CTO and COO, China. “Together, we will help promote the acceleration and development of China’s emerging bio-pharmaceutical industry.”
Xiaofan Zhang, Vice Director of Liaoning (Benxi) Bio-pharmaceutical Industry Base, commented, “Liaoning (Benxi) Bio-pharmaceutical Industry is committed to becoming the ‘pharmaceutical valley’ in northern China; with HUYA’s knowledge and capacity in international drug development, Liaoning (Benxi) Bio-pharmaceutical Industry Base hopes to solidify its position as a leading medical and pharmaceutical base in China.”
About HUYA Bioscience International
HUYA is the leader in global pharmaceutical co-development with Chinese partners. With seven offices strategically located in China, the most comprehensive Chinese compound portfolio, and a rapidly growing number of exclusive agreements with premier Chinese research and development organizations, HUYA is uniquely positioned to identify and license novel Chinese compounds. HUYA offers Western pharmaceutical companies efficient access to innovative therapeutic opportunities and helps to reduce deal-making complexity in China. The company has become a champion of guiding China’s biomedical innovations to the worldwide marketplace. HUYA has joint headquarter offices in San Diego, CA, USA and Shanghai, China. Additional information about the company is available at www.huyabio.com.
About Liaoning (Benxi) Bio-Pharmaceutical Industry Base
Liaoning (Benxi) Bio-pharmaceutical Industry Base is situated in between Benxi and the Liaoning provincial capital, Shenyang. It spans an area of 205 square km. Up to date, 264 enterprises have invested a total of 73.9 billion RMB ($11.4 billion) in the pharmaceutical base, with accumulated production capacity of 98 billion RMB ($15.1 billion). In 2010, with the approval from Ministry of Science and Technology, Liaoning (Benxi) Bio-pharmaceutical Industry Base formally became a national-level high-tech industry base. For more information, please visit www.benxi.gov.cn.
Yung-Chih Wang, Ph.D., MBA
Vice President, Corporate Development
China HUYA Bioscience International
Qing (Vicky) Xia, MS, MBA
Senior Business Development Manager
HUYA Bioscience International